Literature DB >> 31804861

Role of Capecitabine in Early Breast Cancer.

Asya N Varshavsky-Yanovsky1, Lori J Goldstein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31804861      PMCID： PMC6968794          DOI： 10.1200/JCO.19.02946

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  19 in total

1.  Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine.

Authors:  Joyce O'Shaughnessy; Hartmut Koeppen; Yuanyuan Xiao; Mark R Lackner; Devchand Paul; Christopher Stokoe; John Pippen; Lea Krekow; Frankie Ann Holmes; Svetislava Vukelja; Deborah Lindquist; Scot Sedlacek; Ragene Rivera; Robert Brooks; Kristi McIntyre; Carrie Brownstein; Silke Hoersch; Joanne L Blum; Stephen Jones
Journal:  Clin Cancer Res       Date:  2015-06-03       Impact factor: 12.531

2.  Response-guided neoadjuvant chemotherapy for breast cancer.

Authors:  Gunter von Minckwitz; Jens Uwe Blohmer; Serban Dan Costa; Carsten Denkert; Holger Eidtmann; Wolfgang Eiermann; Bernd Gerber; Claus Hanusch; Jörn Hilfrich; Jens Huober; Christian Jackisch; Manfred Kaufmann; Sherko Kümmel; Stefan Paepke; Andreas Schneeweiss; Michael Untch; Dirk Michael Zahm; Keyur Mehta; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

3.  Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

Authors:  J L Blum; S E Jones; A U Buzdar; P M LoRusso; I Kuter; C Vogel; B Osterwalder; H U Burger; C S Brown; T Griffin
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

4.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

Authors:  Gunter von Minckwitz; Michael Untch; Jens-Uwe Blohmer; Serban D Costa; Holger Eidtmann; Peter A Fasching; Bernd Gerber; Wolfgang Eiermann; Jörn Hilfrich; Jens Huober; Christian Jackisch; Manfred Kaufmann; Gottfried E Konecny; Carsten Denkert; Valentina Nekljudova; Keyur Mehta; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2012-04-16       Impact factor: 44.544

5.  Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.

Authors:  Hyman B Muss; Mei-Yin C Polley; Donald A Berry; Heshan Liu; Constance T Cirrincione; Maria Theodoulou; Ann M Mauer; Alice B Kornblith; Ann H Partridge; Lynn G Dressler; Harvey J Cohen; Patricia A Kartcheske; Edith A Perez; Antonio C Wolff; Julie R Gralow; Harold J Burstein; Ahmad A Mahmood; Linda M Sutton; Gustav Magrinat; Barbara A Parker; Ronald D Hart; Debjani Grenier; Arti Hurria; Aminah Jatoi; Larry Norton; Clifford A Hudis; Eric P Winer; Lisa Carey
Journal:  J Clin Oncol       Date:  2019-07-24       Impact factor: 44.544

6.  Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.

Authors:  Miguel Martín; Amparo Ruiz Simón; Manuel Ruiz Borrego; Nuria Ribelles; Álvaro Rodríguez-Lescure; Montserrat Muñoz-Mateu; Sonia González; Mireia Margelí Vila; Agustí Barnadas; Manuel Ramos; Sonia Del Barco Berron; Carlos Jara; Lourdes Calvo; Noelia Martínez-Jáñez; César Mendiola Fernández; César A Rodríguez; Eduardo Martínez de Dueñas; Raquel Andrés; Arrate Plazaola; Juan de la Haba-Rodríguez; Jose Manuel López-Vega; Encarna Adrover; Ana Isabel Ballesteros; Ana Santaballa; Pedro Sánchez-Rovira; José M Baena-Cañada; Maribel Casas; María del Carmen Cámara; Eva Maria Carrasco; Ana Lluch
Journal:  J Clin Oncol       Date:  2015-09-28       Impact factor: 44.544

7.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

8.  Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.

Authors:  Heikki Joensuu; Pirkko-Liisa Kellokumpu-Lehtinen; Riikka Huovinen; Arja Jukkola-Vuorinen; Minna Tanner; Riitta Kokko; Johan Ahlgren; Päivi Auvinen; Outi Lahdenperä; Sanna Kosonen; Kenneth Villman; Paul Nyandoto; Greger Nilsson; Paula Poikonen-Saksela; Vesa Kataja; Jouni Junnila; Petri Bono; Henrik Lindman
Journal:  JAMA Oncol       Date:  2017-06-01       Impact factor: 31.777

Review 9.  Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer.

Authors:  Georges El Hachem; Andrea Gombos; Ahmad Awada
Journal:  F1000Res       Date:  2019-04-30

10.  Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).

Authors:  Ana Lluch; Carlos H Barrios; Laura Torrecillas; Manuel Ruiz-Borrego; Jose Bines; Jose Segalla; Ángel Guerrero-Zotano; Jose A García-Sáenz; Roberto Torres; Juan de la Haba; Elena García-Martínez; Henry L Gómez; Antonio Llombart; Javier Salvador Bofill; José M Baena-Cañada; Agustí Barnadas; Lourdes Calvo; Laura Pérez-Michel; Manuel Ramos; Isaura Fernández; Álvaro Rodríguez-Lescure; Jesús Cárdenas; Jeferson Vinholes; Eduardo Martínez de Dueñas; Maria J Godes; Miguel A Seguí; Antonio Antón; Pilar López-Álvarez; Jorge Moncayo; Gilberto Amorim; Esther Villar; Salvador Reyes; Carlos Sampaio; Bernardita Cardemil; Maria J Escudero; Susana Bezares; Eva Carrasco; Miguel Martín
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544
View more
  2 in total

1.  Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years.

Authors:  Lisi M Dredze; Michael Friger; Samuel Ariad; Michael Koretz; Bertha Delgado; Ruthy Shaco-Levy; Margarita Tokar; Michael Bayme; Ravit Agassi; Maia Rosenthal; Victor Dyomin; Olga Belochitski; Shai Libson; Tamar Mizrahi; David B Geffen
Journal:  Breast Cancer Res Treat       Date:  2022-04-22       Impact factor: 4.872

2.  The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.

Authors:  Xingfa Huo; Jinming Li; Jiuda Zhao; Fuxing Zhao; Dengfeng Ren; Raees Ahmad; Xinyue Yuan; Feng Du
Journal:  BMC Cancer       Date:  2021-01-19       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.